Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ensysce Biosciences, Inc. (ENSC : NSDQ)
 
 • Company Description   
Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp., is based in SAN DIEGO.

Number of Employees: 7

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.31 Daily Weekly Monthly
20 Day Moving Average: 54,570 shares
Shares Outstanding: 2.37 (millions)
Market Capitalization: $5.48 (millions)
Beta: 0.98
52 Week High: $14.67
52 Week Low: $1.62
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -1.28% -6.63%
12 Week 22.87% 3.08%
Year To Date -71.62% -73.42%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7946 IVANHOE AVENUE SUITE 201
-
LA JOLLA,CA 92037
USA
ph: 858-263-4196
fax: -
shannon@mzgroup.us http://www.ensysce.com
 
 • General Corporate Information   
Officers
Lynn Kirkpatrick - Chief Executive Officer; President and Director
Bob Gower - Chairman and Director
David Humphrey - Chief Financial Officer; Secretary and Treasurer
Andrew Benton - Director
William Chang - Director

Peer Information
Ensysce Biosciences, Inc. (CORR.)
Ensysce Biosciences, Inc. (RSPI)
Ensysce Biosciences, Inc. (CGXP)
Ensysce Biosciences, Inc. (BGEN)
Ensysce Biosciences, Inc. (GTBP)
Ensysce Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 293602504
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 2.37
Most Recent Split Date: 12.00 (0.07:1)
Beta: 0.98
Market Capitalization: $5.48 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.82 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.94 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.01
Price/Cash Flow: -
Price / Sales: 0.88
EPS Growth
vs. Year Ago Period: 83.14%
vs. Previous Quarter: 52.07%
Sales Growth
vs. Year Ago Period: 331.37%
vs. Previous Quarter: 1.23%
ROE
06/30/25 - -
03/31/25 - -192.54
12/31/24 - -214.99
ROA
06/30/25 - -
03/31/25 - -121.77
12/31/24 - -139.80
Current Ratio
06/30/25 - -
03/31/25 - 2.50
12/31/24 - 2.42
Quick Ratio
06/30/25 - -
03/31/25 - 2.50
12/31/24 - 2.42
Operating Margin
06/30/25 - -
03/31/25 - -109.49
12/31/24 - -153.27
Net Margin
06/30/25 - -
03/31/25 - -109.49
12/31/24 - -153.27
Pre-Tax Margin
06/30/25 - -
03/31/25 - -109.49
12/31/24 - -153.30
Book Value
06/30/25 - -
03/31/25 - 1.15
12/31/24 - 2.59
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©